Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Cancer Res. 2010 Jun 1;70(13):5549–5557. doi: 10.1158/0008-5472.CAN-09-4254

Figure 5. Molecular characterisation of melanocytic lesions.

Figure 5

A. PCR-mediated genotyping for recombined G12VKRAS (lox-G12VKRAS; 240bp) from a dorsally located (Tumor A) and perianal (Tumor B) tumor. Kidney DNA was used as a negative control and Tyr::CreERT2 is present in all three samples.

B. Double immunofluorescence staining for p16INK4a (p16; green) and S100 (red) in a G12VKRAS-driven tumor. DAPI nuclear staining (blue) reveals the nuclei and a merged image is shown.

C. Western blot for Tp53 in three G12VKRAS-driven tumor cell lines (#8352, #5954, #4755) treated with DMSO (control) or doxorubicin (1μM; 8hr). Erk2 is used as a loading control.

D. RT-PCR analysis for expression of Tyrosinase (Tyr.), Dct, Pax3, Silver (Si/gp100) and Gapdh (loading control). Tumors were taken from a section of TM-treated skin (Tumor A) or from the perianal region (Tumor B). The indicated tissues were also analysed from at TM-treated G12VKRAS;CreERT2 (G12VKRAS) or control (WT) mouse.